Leon F Garcia-Martinez

This inventor holds 89 USPTO granted patents, plus 9 CIPO patents and 3 EPO patents, primarily in Monoclonal Antibodies (CPC class A61K2039-505). Top assignees: Alderbio Holdings LLC, H. Lundbeck A/s, University of Iowa Research Foundation. Active years: 2009-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Leon F Garcia-Martinez. Retrieved from https://idiyas.com/inventor/leon-f-garcia-martinez

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 89

% Patents Active = 64.0

CIPO Patents = 9 (Patent Applications = 12)

EPO Patents = 3 (Patent Applications = 9)

Average Co-Inventor Count = 7.7

ph-index = 14

Forward Citations = 678(Granted Patents)

Forward Citations (Not Self Cited) = 407(Dec 10, 2025)

Inventors with similar research interests:

🔬 See more inventors

Location History:

Seattle, WA (US) (2017)
Woodinville, WA (US) (2009 - 2023)

Company Filing History:

59 out of 98

Alderbio Holdings LLC

University of Iowa Research Foundation

patents

4. 4 out of 8

Alder Biopharmaceuticals, Inc.

7. 1 out of 834,659

Other

patents

where one patent can have more than one assignee

Years Active: 2009-2026

Loading Chart...

Areas of Expertise:

Anti-ACTH Antibodies

Anti-IL-6 Antibodies

Anti-CGRP Antibodies

Anti-PACAP Antibodies

Humanized Antibodies

Multi-Subunit Proteins

Antibody Fragments

Photophobia Treatment

Diarrhea Treatment

Inflammation Prevention

Autoimmunity Treatment

Antibody Purification

89 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12545725 - Anti-PACAP antibodies, nucleic acids and methods of making thereof (2026-02-10),

2. 12351627 - Anti-ACTH antibodies and use thereof (2025-07-08),

3. 11827700 - Treatment or prevention of diseases and disorders associated with cells that express IL-6 with Anti-IL-6 antibodies (2023-11-28),

4. 11427631 - Anti-ACTH antibodies and use thereof (2022-08-30),

5. 11352409 - Anti-PACAP antibodies and uses thereof (2022-06-07),

6. 11325967 - Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light a version in subjects in need thereof, especially migraine sufferers (2022-05-10),

7. 11254741 - Anti-PACAP antibodies (2022-02-22),

8. 11225667 - Multi-copy strategy for high-titer and high-purity production of multi-subunit proteins such as antibodies in transformed microbes such as (2022-01-18),

9. 11214610 - High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as (2022-01-04),

10. 11117960 - Humanized anti-ACTH antibodies and use thereof (2021-09-14),

11. 11111289 - Anti-CGRP compositions and use thereof (2021-09-07),

12. 11027018 - Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels (2021-06-08),

13. 10981985 - Anti-PACAP antibodies (2021-04-20),

14. 10981984 - Methods of determining whether anti-PACAP antibodies inhibit PACAP-associated photophobia or light aversion (2021-04-20),

15. 10975135 - Humanized anti-PACAP antibodies (2021-04-13),

Title: Innovator Spotlight: Leon F Garcia-Martinez - Pioneering Advances in Disease Treatment

Introduction:

Leon F Garcia-Martinez is a highly accomplished inventor based in Seattle, WA, who has made significant contributions in the field of healthcare through his groundbreaking inventions. With a remarkable total of 87 patents to his name, Garcia-Martinez has been a driving force in the development of revolutionary treatments for various diseases and disorders.

Latest Patents:

Among his latest patents is the groundbreaking work on "Treatment or prevention of diseases and disorders associated with cells that express IL-6 with Anti-IL-6 antibodies." This innovation centers around the development of antibodies targeting IL-6, with applications in the diagnosis and treatment of illnesses linked to this protein. Another notable invention is "Anti-ACTH antibodies and use thereof," which focuses on the use of antibodies to target ACTH and addresses conditions such as Cushing's Disease, Parkinson's disease, and diabetes, among others.

Career Highlights:

Garcia-Martinez has held key roles in prominent organizations within the biopharmaceutical industry, including Alderbio Holdings LLC and H. Lundbeck A/s. His expertise and leadership have been instrumental in driving forward the development and commercialization of cutting-edge healthcare solutions.

Collaborations:

Throughout his career, Garcia-Martinez has collaborated with esteemed professionals in the field, such as John A Latham and Benjamin H Dutzar. These collaborations have fostered innovation and led to the successful implementation of new technologies in healthcare.

Conclusion:

Leon F Garcia-Martinez stands as a trailblazer in the realm of healthcare innovation, with a prolific track record of patents that have significantly advanced the field of disease treatment and prevention. His dedication to pioneering research and collaboration with industry leaders underscores his relentless pursuit of better health outcomes for individuals worldwide.

Profile summary based on public USPTO records.